Skip to main content

Cytologic and histologic samples from patients infected by the novel coronavirus 2019 SARSCoV2

An italian institutional experience focusing on biosafety procedures

This commentary provides an overview of laboratory biosafety related to the testing of histological and cytological specimens from Italian patients infected with the novel pathogen first identified in Wuhan, China, at the end of 2019 and known as the novel coronavirus 2019?nCoV or 2019 SARS?CoV?2.